Literature DB >> 8149338

Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR).

N Tradati1, F Chiesa, N Rossi, R Grigolato, F Formelli, A Costa, G de Palo.   

Abstract

Eight patients with diffuse (non-operable) pre-cancerous lesions (oral lichen or leukoplakias) were treated with fenretinidec (4-HPR) applied topically twice daily. After one month of therapy two patients had complete remission and the other six had a greater than 75% response. 4-HPR was well tolerated, and no local or distant side effects were observed. Topical treatment may be combined with oral administration at lower doses to obtain therapeutic results with less toxicity than observed with oral administration alone. A study to further evaluate the efficacy of topical treatment is in progress at our institute.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149338     DOI: 10.1016/0304-3835(94)90385-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Evaluation of a mucoadhesive fenretinide patch for local intraoral delivery: a strategy to reintroduce fenretinide for oral cancer chemoprevention.

Authors:  Andrew S Holpuch; Maynard P Phelps; Kashappa-Goud H Desai; Wei Chen; George M Koutras; Byungdo B Han; Blake M Warner; Ping Pei; Garrett A Seghi; Meng Tong; Michael B Border; Henry W Fields; Gary D Stoner; Peter E Larsen; Zhongfa Liu; Steven P Schwendeman; Susan R Mallery
Journal:  Carcinogenesis       Date:  2012-03-15       Impact factor: 4.944

2.  Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).

Authors:  M M Webber; D Bello-DeOcampo; S Quader; N D Deocampo; W S Metcalfe; R M Sharp
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

3.  A review of the nonsurgical treatment of oral leukoplakia.

Authors:  Adriana Spinola Ribeiro; Patrícia Ribeiro Salles; Tarcília Aparecida da Silva; Ricardo Alves Mesquita
Journal:  Int J Dent       Date:  2010-02-23

4.  4-oxo-N-(4-hydroxyphenyl)retinamide: two independent ways to kill cancer cells.

Authors:  Paola Tiberio; Elena Cavadini; Gabriella Abolafio; Franca Formelli; Valentina Appierto
Journal:  PLoS One       Date:  2010-10-14       Impact factor: 3.240

5.  Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.

Authors:  Andrew S Holpuch; Kashappa-Goud H Desai; Steven P Schwendeman; Susan R Mallery
Journal:  J Carcinog       Date:  2011-09-21

6.  Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors.

Authors:  Paola Tiberio; Elena Cavadini; Loredana Cleris; Sabrina Dallavalle; Loana Musso; Maria G Daidone; Valentina Appierto
Journal:  Front Pharmacol       Date:  2017-04-26       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.